Mather Group’s BeOne Medicines Ltd ONC Stock Holding History

Mather Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12K	Buy	25 +3	+14%	+$884	﹤0.01%	1563
2026 Q1	$6.53K	Buy	+22	New	+$7.12K	﹤0.01%	1530
2025 Q4	–	Sell	-22	Closed	-$7.5K	–	1703
2025 Q3	$7.5K	Buy	+22	New	+$6.68K	﹤0.01%	1318
2025 Q2	–	Sell	-22	Closed	-$5.99K	–	1783
2025 Q1	$5.99K	Buy	22 +9	+69%	+$2.1K	﹤0.01%	1369
2024 Q4	$2.4K	Hold	13	–	–	﹤0.01%	1508
2024 Q3	$2.92K	Buy	+13	New	+$2.34K	﹤0.01%	1409
2024 Q2	–	Sell	-4	Closed	-$721	–	2287
2024 Q1	$721	Buy	+4	New	+$644	﹤0.01%	1659

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mather Group's ONC Position: Q2 2026 in Review

Mather Group increased its BeOne Medicines Ltd (ONC) stake by 14% in Q2 2026, buying an estimated $884 and bringing the position to 25 shares worth $7.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1563.

Mather Group first reported a position in ONC in Q1 2024 and has held it in 7 quarters since. The position peaked at $7.5K in Q3 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Mather Group held 25 shares of BeOne Medicines Ltd worth $7.12K as of Q2 2026.
Mather Group bought 3 BeOne Medicines Ltd shares in Q2 2026, an estimated $884.
BeOne Medicines Ltd made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1563 holding.
Mather Group first reported a position in BeOne Medicines Ltd in Q1 2024 and has held it in 7 quarters since.
Mather Group's BeOne Medicines Ltd position peaked at $7.5K in Q3 2025.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.